Cancer Vaccine Phase 3: 5 Biotechs On the Brink

$Moderna, Inc.(MRNA)$ just showed how explosive a successful cancer-vaccine catalyst can be.

A $1,000 overnight options bet reportedly turned into more than $7.3M after Moderna announced a major Phase 3 win for its personalized cancer vaccine program.

But here's the catch:

This is an extremely high-risk game.

Two cancer-vaccine Phase 3 programs have already failed in 2026, including $IOBT, which filed for Chapter 7 after missing its primary endpoint, and $IMMP, which discontinued its Phase 3 program for futility.

So the next wave of catalysts could create massive winners — or wipe out years of work.

Here are 5 biotech names with major clinical readouts ahead:

1. $CG Oncology Inc.(CGON)$

Oncolytic virus delivered directly into the bladder for intermediate-risk bladder cancer.

PIVOT-006: Topline data guided for the near term.
BLA completion: Q4 2026

2. $Summit Therapeutics PLC(SMMT)$

Bispecific antibody targeting PD-1 + VEGF in first-line lung cancer.

HARMONi-3: Final PFS + interim OS expected in 2H 2026.
PDUFA: Nov. 14, 2026

3. $BriaCell Therapeutics Corp.(BCTX)$

Off-the-shelf cell-based vaccine combined with a checkpoint inhibitor for metastatic breast cancer.

Bria-ABC: Interim OS data expected after 144 events.
Topline: 2026
Fast Track designation

This one is a micro-cap, which also means the risk — and potential volatility — is much higher.

4. $Greenwich Lifesciences Inc(GLSI)$

HER2 peptide vaccine designed to prevent recurrence following surgery in breast cancer patients.

FLAMINGO-01: Event-driven interim analyses at 28 and 56 events.
Target HR: 0.55

5. $Immunocore Holdings plc(IMCR)$

T-cell engager targeting gp100 in previously treated advanced cutaneous melanoma.

TEBE-AM: Enrollment completed in 1H 2026.
Topline: Potentially as early as 2H 2026

Same tumor type being studied in INTerpath-001.

⚠️ The important part

$MRNA's success doesn't make these five the "next MRNA."

It shows just how much upside exists when a cancer vaccine or immunotherapy finally produces convincing late-stage data.

But the failure rate is brutal.

$IO Biotech, Inc.(IOBT)$ → Chapter 7
$Immutep Limited(IMMP)$ → Phase 3 stopped for futility

And that's the point:

This is not a basket of guaranteed winners.

It's a basket of binary clinical catalysts.

One positive Phase 3 result can completely reset a company's valuation.

One failed endpoint can do the opposite.

Huge upside. Huge downside.

Size accordingly. 🎯

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.